---
layout: default
title: Melatonin
parent: 僅模型預測 (L5)
nav_order: 281
evidence_level: L5
indication_count: 0
---

# Melatonin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Melatonin: Drug Repurposing Evaluation — No TxGNN Prediction Data Available

---

## One-Sentence Summary

Melatonin (DB01065) is an endogenous neurohormone primarily associated with circadian rhythm regulation and sleep-wake cycle management. The current Evidence Pack contains **no TxGNN predicted indications** and carries two unresolved data gaps — one of which is classified as Blocking — meaning a formal repurposing evaluation cannot be completed at this stage. This report documents the current state of the evidence and outlines the steps needed before any repurposing decision can be made.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not specified in Evidence Pack |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — pipeline has not produced output |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

No TxGNN prediction has been generated for this drug in the current Evidence Pack, so no mechanistic rationale for a new indication can be formally presented.

For general context: Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone synthesised primarily by the pineal gland. Based on publicly available pharmacological knowledge, it acts on G protein-coupled melatonin receptors MT1 and MT2, mediating entrainment of the circadian rhythm and sleep-wake transitions. It is also recognised as having antioxidant properties. The Evidence Pack, however, flags the mechanism of action as a **High-severity data gap** (DG002), meaning formal MOA documentation has not yet been retrieved from DrugBank.

Until the TxGNN prediction pipeline is re-run and produces candidate indications, this section will remain incomplete.

---

## Clinical Trial Evidence

No TxGNN prediction has been generated for this drug. No disease-specific clinical trial evidence is presented in this Evidence Pack.

> Currently no related clinical trials registered in the Evidence Pack.

---

## Literature Evidence

No TxGNN prediction has been generated for this drug. No disease-specific literature evidence is presented in this Evidence Pack.

> Currently no related literature available in the Evidence Pack.

---

## Denmark Market Information

Melatonin is not currently recorded as marketed in Denmark within this Evidence Pack. No marketing authorisations from the Danish Medicines Agency (Laegemiddelstyrelsen) are on file.

| Item | Detail |
|------|--------|
| Market Status | Not marketed in Denmark (per Evidence Pack) |
| Total Authorisations | 0 |

> **Note for reviewers:** Melatonin is authorised in the European Union under the brand name **Circadin® 2 mg prolonged-release tablet** (EMA centralised procedure) for the short-term treatment of primary insomnia in patients aged 55 years and over. This authorisation does not appear in the current Evidence Pack, which may indicate a data collection gap rather than a true absence of authorisation. Verification against the Laegemiddelstyrelsen product database is recommended before concluding that melatonin is entirely unregistered in Denmark.

---

## Safety Considerations

All safety fields in this Evidence Pack are flagged as data gaps and cannot be reported.

> Please refer to the approved Summary of Product Characteristics (SmPC) — for example, the EMA-authorised Circadin SmPC — for current safety information, including warnings, contraindications, and drug interactions.

**Outstanding data gaps preventing safety assessment:**

| Gap ID | Missing Item | Severity | Impact | Suggested Remediation |
|--------|-------------|----------|--------|----------------------|
| DG001 | Regulatory warnings and contraindications | **Blocking** | Cannot complete safety pre-screening (S1 gate) | Download and parse SmPC PDF from Laegemiddelstyrelsen or EMA website |
| DG002 | Mechanism of action (MOA) | High | Mechanistic link analysis cannot be performed | Query DrugBank API for DB01065 |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline has not produced any predicted indications for melatonin in this Evidence Pack version (v4, data cut-off 2026-04-04), and a Blocking data gap (DG001 — missing regulatory warnings and contraindications) prevents even preliminary safety screening. No repurposing evaluation can proceed until these issues are resolved.

**To proceed, the following is needed:**

- **[Blocking]** Resolve DG001: Retrieve current SmPC warnings and contraindications from Laegemiddelstyrelsen or the EMA product database
- **[High]** Resolve DG002: Query DrugBank API for DB01065 to obtain formal MOA documentation
- **Re-run the TxGNN prediction pipeline** after data gaps are resolved to generate candidate indications
- **Verify Denmark registration status**: Cross-check whether Circadin® or any melatonin product currently holds a national or centralised authorisation valid in Denmark, as the 0-licence count in this Evidence Pack may reflect a data collection issue
- **Update the Evidence Pack** to version v5 once the above steps are completed, and re-submit for formal evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

